Cyclarity Therapeutics - Longevity with cyclodextrins
Cyclarity Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.
UDP-003 drives the excretion of 7KC from animal cells and tissues, confirming its potential as a first-in-class approach for an unserved target underlying atherosclerosis
The problem: atherosclerosis causes 4 in 10 deaths worldwide
The status quo: treatments for atherosclerosis, such as statins, only manage symptoms but do not address the underlying cause
The result: cardiovascular disease remains the #1 global killer and costs trillions of dollars
Cyclarity Therapeutics was awarded one of the first ‘Innovation Passports’ under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) in 2021. The program provides enhanced early development input, accelerated assessment, rolling clinical reviews, and adaptive authorization.
According to information published recently, phase 1 trials are to begin in early 2025. Phase 2 readout should be complete in 2026. All early-stage trials will include imaging components to measure plaque impact.
Why Cyclodextrins?
Cyclodextrins have a hydrophilic shell (attracted to and soluble in water), but a hydrophobic core (repels water and is non-polar). This means that our engineered cyclodextrins can attract and encapsulate hydrophobic molecules, and then contain them in a manner that can be dissolved in water, and thus purged from the bloodstream.
Unlike current drugs on the market and in development, our engineered cyclodextrins will be disease modifying – that is have the potential to reverse the course of cardiovascular disease. They will additionally server to prevent the onset of future pathologies, and will protect against the accumulation of oxidized cholesterol in the first place.
领英推荐
If you like these brief communications,?Subscribe?to join 4400 cyclodextrin enthusiasts, and gain and share knowledge on current and novel applications, challenges, and possibilities.
Proposed Mechanism of Action
Cyclarity's Lead Product: UDP-003 is a first-in-class drug; a specially engineered cyclodextrin which will target and remove toxic oxidized cholesterol, a key driver of atherosclerosis, neurodegenerative diseases, and other chronic diseases. UDP-003 is designed to restore the cardiovascular self-repair function and reduce arterial plaque.
You can learn more about the technology and in vitro results from a paper published earlier by the group: https://pmc.ncbi.nlm.nih.gov/articles/PMC10634755/
The Cyclarity Platform?
Synthetic chemistry for cyclodextrins is very promising but also both extremely expensive and time-consuming. So Cyclarity built a proprietary discovery tool – The Cyclarity Platform. With it, they are able to model cyclodextrins and run virtual experiments, performing complex measurements of molecular-dynamic combinations between potential cyclodextrin forms and potential targets. These tools can also run very broad-based docking analyses with these to test a variety of candidates against hundreds of possible on-target (and potential off-target) effects.
The Cyclarity Platform allows for the testing of thousands of cyclodextrin candidates against thousands of both targeted and non-targeted molecules.
With an iterative process of improvement, the platform provides exceptional opportunities in a broad spectrum of molecular dynamics, including:
Cyclarity's mission is to reduce the multi-trillion-dollar burden of heart disease and save countless lives.
The company is developing further applications for UDP-003 and other cyclodextrin-based therapies in its pipeline.